We are developing a prototype droplet-based microfluidics system for single-cell transcriptomic, epigenetic and phenotypic analysisas well as paired TCR α-β chain sequencing of immune cells.
Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Despite the improved patient survival achieved with the advent of immunotherapies, about 60-70% of patients don’t respond to treatment or relapse later on. This underscores the need for understanding the evasion/resistance immune mechanisms within the tumor microenvironment (including myeloid cells and T lymphocytes) that hinder an effective anti-tumor immunity.
This powerful droplet-based microfluidics system will provide unprecedented information on single-cell heterogeneity of tumor-infiltrating immune cells and the complexity of their interactions with other cells within the tumor, thereby paving the way for cancer biomarker and therapeutic target discovery.
The candidate will apply bioinformatics analysis on transcriptomic (scRNA-Seq), epigenetic (scChIP-Seq) and phenotypic (Ab-Seq) data to improve our understanding of the evasion/resistance immune mechanisms within the tumor microenvironment.
In close collaboration with wet lab postdocs and students, he/she will help design experiments and will be in charge of integrating and interpreting comprehensive next generation sequencing datasets:
- Single-cell next-Generation Sequencing data (including ChIP-Seq and RNA-Seq)
- Pathways and Enrichment analyses (Networks, Functional, Transcription Factor Binding Sites…).
He/she will benefit from strong interactions within the bioinformatics team in the “Immunity and Cancer” unit headed by Sebastian Amigorena (15 people) and in the LBC/ESPCI headed by Andrew Griffiths (25 people)